Abstract:ID 93958 Poster Board 481 A 3 adenosine receptor (AR) agonists are being developed for the treatment of autoimmune inflammatory diseases, chronic pain and cancer. A 3 AR agonists are not limited by cardiovascular side effects observed with other adenosine (A 1 and A 2A ) agonists that were in clinical trials. 2-Arylethynyl (North)-methanocarba adenosines have been explored as highly selective A 3 AR agonists, which is largely a function of the pseudoribose (bicyclic fused cyclopropane and cyclopentane) ring that pre-establishes a preferred (N) conformation for receptor recognition. Here, we compare analogues in the 5¢methylamide series having bulky C2-substitution, which either contain or lack an ethynyl spacer between adenine and a cyclic group. 2-Aryl compounds 11 , 13 , 14 , 19 , 22 , 23 , 27 , 29 , 31 and 34 , lacking an ethynyl spacer, displayed potent K i values of 2–30 nM at the human (h) A 3 AR, while other derivatives had greatly reduced affinity. The mouse (m) A 3 AR affinity was highly variable, with 2-arylethynyl groups greatly favoring high affinity ( 7 , 8 > 3c , 3d > 3b ) compared to 2-aryl analogues. However, 4¢truncated derivatives lacking a 2-ethynyl spacer had greatly reduced hA 3 AR affinity, even for those analogues containing affinity-enhancing N 6 -dopamine-derived substituents. This suggests that the 5¢methylamide group is especially important for anchoring these analogues in a deep hydrophilic subpocket in the receptor. hA 3 AR homology modeling indicated that 2-aryl and 2-arylethynyl groups have different conformations and receptor environments. The directly connected 2-aryl groups interact with ECL2 of the hA 3 AR, as opposed to the 2-arylethynyl groups, which interact with TM2. Functional assays of selected compounds in G protein-dependent and independent signaling were performed using engineered HEK293T cell lines. In a hA 3 AR miniG α i recruitment assay, 31 (MRS8062) was (slightly) more potent compared to a β-arrestin2 recruitment assay, and its maximal efficacy (E max ) was much higher (165%) than reference nonselective agonist NECA. Thus, in the 2-aryl series, A 3 AR affinity and selectivity were variable and generally reduced compared to the 2-arylethynyl series, with a greater dependence on the specific aryl group present. Selected compounds were protective in an vivo ischemic model of peripheral artery disease (PAD), in which other A 3 AR agonists demonstrated efficacy. Compounds 3a – 3c in the rigidified 2-arylethynyl series significantly decreased the % cell death in this model of skeletal muscle ischemia reperfusion injury/claudication, as previously shown only for moderately A 3 AR-selective ribosides or (N)-methanocarba derivatives (all lacking the 2-arylethynyl group). Thus, we have expanded A 3 AR agonist SAR for (N)-methanocarba adenosines and their application to skeletal muscle ischemia. NIDDK Intramural Res. ZIADK031117

2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization

2-Substituted -Methanocarba A3 Adenosine Receptor Agonists: In silico, in vitro and in vivo Characterization

Methanocarba Analogues of Purine Nucleosides As Potent and Selective Adenosine Receptor Agonists.

A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity

Synthesis and biological evaluation of sugar-modified truncated carbanucleosides as A 2A and A 3 adenosine receptor ligands to explore conformational effect to the receptors

Pyran Template Approach to the Design of Novel A3 Adenosine Receptor Antagonists

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

Medicinal chemistry of adenosine A3 receptor ligands

Synthesis of Adenosine Analogues with Indole Moiety As Human Adenosine A3 Receptor Ligands.

Selective A(3) Adenosine Receptor Antagonists: Water-Soluble 3, 5-Diacyl-1,2,4-trialkylpyridinium Salts and Their Oxidative Generation from Dihydropyridine Precursors.

Exploring C2 and N6 Substituent Effects on Truncated 4'‐Thioadenosine Derivatives as Dual A2A and A3 Adenosine Receptor Ligands

N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides As A2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy.

Structure−Activity Relationships of New 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as Allosteric Enhancers of the A<sub>3</sub>Adenosine Receptor

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.

2,6-Diaryl-4-phenacylaminopyrimidines As Potent and Selective Adenosine A(2A) Antagonists with Reduced Herg Liability.

Species differences and mechanism of action of A3 adenosine receptor allosteric modulators

Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor

Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists

Molecular Modeling Studies of Human A3 Adenosine Antagonists: Structural Homology and Receptor Docking

Insight into the binding mode and the structural features of the pyrimidine derivatives as human A2A adenosine receptor antagonists.